8-甲氧基-2-甲基喹唑啉-4(3h)-酮 | 90915-45-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 8-甲氧基-2-甲基喹唑啉-4(3h)-酮
• 中文别名: 8-甲氧基-2-甲基喹唑啉-4(3H)-酮
• 英文名称: 8-methoxy-2-methylquinazolin-4(3H)-one
• 英文别名: 8-methoxy-2-methyl-4-oxo-3,4-dihydroquinazoline；NU 1063；8-Methoxy-2-methyl-4(3H)-quinazolinone；8-methoxy-2-methyl-3H-quinazolin-4-one
• CAS: 90915-45-0
• 化学式: C₁₀H₁₀N₂O₂
• mdl: MFCD09753619
• 分子量: 190.202
• InChiKey: ZWCBMSNYXIFTCM-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 储存条件：
  存放在室温、密封且干燥的环境中。

反应信息

• 作为反应物：
  描述：

  8-甲氧基-2-甲基喹唑啉-4(3h)-酮 在 三溴化硼 、 potassium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 34.0h， 生成 8-羟基-2,3-二甲基-4(3H)-喹唑啉酮
  参考文献：
  名称：

  Resistance-Modifying Agents. 5. Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP)

  摘要：

  Clinical studies concerning the role of poly(ADP-ribose) polymerase (PARP) in the repair of drug- and radiation-induced DNA damage have been impeded by the poor solubility, lack of potency, and limited specificity of currently available inhibitors. A series of 2-alkyl- and 2-aryl-substituted 8-hydroxy-, 8-methoxy-, and 8-methylquinazolin-4(3H)-ones has been synthesized and evaluated for PARP inhibitory activity in permeabilized L1210 murine leukemia cells. 8-Methoxy- and 8-methylquinazolinones (14-34) were readily prepared by acylation of 3-substituted anthranilamides with the appropriate acid chloride, followed by base-catalyzed cyclization. The requisite 8-hydroxyquinazolinones (6, 35-39) were synthesized by demethylation of the corresponding 8-methoxyquinazolinones with BBr3. N-Methylation of 8-methoxy-2-methylquinazolinone (15) with Mel, followed by O-demethylation by BBr3, afforded the control N-3-methylquinazolinones 42 and 43, respectively. In general, an 8-hydroxy or 8-methyl substituent enhanced inhibitory activity in comparison with an 8-methoxy group. 2-Phenylquinazolinones were marginally less potent than the corresponding 2-methylquinazolinones, but the introduction of an electron-withdrawing or electron-donating 4'-substituent on the 2-aryl ring invariably increased potency. This was particularly evident in the 8-methylquinazolinone series (IC50 values 0.13-0.27 mu M), which are among the most potent PARP inhibitors reported to date. N-3-Methylquinazolinones 42 and 43 were essentially devoid of activity (IC50 values > 100 mu M). In studies with L1210 cells in vitro, a concentration of 200 mu M 8-hydroxy-2-methylquinazolinone (6, NU1025) (IC50 value 0.40 mu M) potentiated the cytotoxicity of the monomethylating agent 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide and gamma-radiation 3.5- and 1.4-fold, respectively, at the 10% survival level.

  DOI：

  10.1021/jm980273t
• 作为产物：
  描述：

  8-Methoxy-2-methyl-2,3-dihydroquinazolin-4(1H)-one 在 palladium 10% on activated carbon 作用下， 以 乙酸乙酯 为溶剂， 反应 24.0h， 以81%的产率得到8-甲氧基-2-甲基喹唑啉-4(3h)-酮
  参考文献：
  名称：

  Penipanoid C，2-（4-羟基苄基）喹唑啉-4（3 H）-one和NU1025的全合成

  摘要：

  报道了使用更绿色的温和深层低共熔溶剂介导的环化策略，并具有良好的总收率，首次合成了戊烷类化合物C和2-（4-羟基苄基）喹唑啉-4（3 H）-one。NU1025药物也可使用类似方案合成。

  DOI：

  10.1016/j.tetlet.2016.08.018

文献信息

• A copper-catalyzed Ritter-type cascade via iminoketene for the synthesis of quinazolin-4(3H)-ones and diazocines
  作者：Takumi Abe、Koshiro Kida、Koji Yamada

  DOI：10.1039/c7cc01406f

  日期：——

  We have developed a copper-catalyzed Ritter-type reaction/cyclization cascade of anthranilic acids and nitriles, affording the quinazolin-4(3H)-ones and diazocines.

  我们已经开发出一种铜催化的Ritter型反应/环化级联反应，用于合成苯甲酸和腈的喹唑啉-4(3H)-酮和二氮杂环化合物。
• Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
  作者：Benjamin D. Dickson、Way Wua Wong、William R. Wilson、Michael P. Hay

  DOI：10.3390/molecules24081559

  日期：——

  Poly(ADP-ribose)polymerase (PARP) inhibitors (PARPi) have recently been approved for the treatment of breast and ovarian tumors with defects in homologous recombination repair (HRR). Although it has been demonstrated that PARPi also sensitize HRR competent tumors to cytotoxic chemotherapies or radiotherapy, normal cell toxicity has remained an obstacle to their use in this context. Hypoxia-activated prodrugs (HAPs) provide a means to limit exposure of normal cells to active drug, thus adding a layer of tumor selectivity. We have investigated potential HAPs of model PARPi in which we attach a bioreducible “trigger” to the amide nitrogen, thereby blocking key binding interactions. A representative example showed promise in abrogating PARPi enzymatic activity in a biochemical assay, with a ca. 160-fold higher potency of benzyl phthalazinone 4 than the corresponding model HAP 5, but these N-alkylated compounds did not release the PARPi upon one-electron reduction by radiolysis. Therefore, we extended our investigation to include NU1025, a PARPi that contains a phenol distal to the core binding motif. The resulting 2-nitroimidazolyl ether provided modest abrogation of PARPi activity with a ca. seven-fold decrease in potency, but released the PARPi efficiently upon reduction. This investigation of potential prodrug approaches for PARPi has identified a useful prodrug strategy for future exploration.

  聚(ADP-核糖)聚合酶(PARP)抑制剂(PARPi)最近被批准用于治疗同源重组修复(HRR)缺陷的乳腺癌和卵巢肿瘤。尽管已证明PARPi也能使HRR功能正常的肿瘤对细胞毒性化疗或放疗敏感，但正常细胞毒性一直是其在该领域应用的障碍。缺氧激活的前药(HAPs)提供了一种限制正常细胞接触活性药物的方法，从而增加了肿瘤选择性的一层。我们研究了模型PARPi的潜在HAPs，在其中我们将一个生物可还原的“触发器”连接到酰胺氮上，从而阻断了关键的结合相互作用。一个代表性的例子在生物化学测定中显示出抑制PARPi酶活性的前景，其中苄基酞嗪酮4的效力大约是相应的模型HAP 5的160倍，但这些N-烷基化化合物在通过放射分解进行单电子还原后并未释放PARPi。因此，我们将研究范围扩展到包含NU1025，一种含有远离核心结合基序的酚的PARPi。由此产生的2-硝基咪唑基醚适度抑制了PARPi活性，其效力降低了大约七倍，但在还原后有效地释放了PARPi。这项对PARPi潜在前药方法的调查确定了一种有用的前药策略，供未来探索。
• [EN] NEUROLOGICALLY-ACTIVE COMPOUNDS<br/>[FR] COMPOSÉS NEUROLOGIQUEMENT ACTIFS
  申请人：PRANA BIOTECHNOLOGY LTD

  公开号：WO2004031161A1

  公开（公告）日：2004-04-15

  The present invention relates to neurologically-active compounds, being heterocyclic compounds having two fused 6-membered rings with a nitrogen atom at position 1 and a hydroxy or mercapto group at position 8 with at least one ring being aromatic. Also disclosed are processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease.

  本发明涉及具有两个融合的6元环，其中第1位置有一个氮原子，第8位置有一个羟基或巯基基团的神经活性化合物，其中至少一个环是芳香环。还公开了制备这些化合物的方法以及它们作为药物或兽药剂的用途，特别是用于治疗神经系统疾病，更具体地说是神经退行性疾病，如阿尔茨海默病。
• Benzamide analogs useful as PARP (ADP-ribosyltransferase, ADPRT) DNA
  申请人：Newcastle University Ventures Limited

  公开号：US05756510A1

  公开（公告）日：1998-05-26

  A range of 3-oxybenzamide compounds and related quinazolinone compounds are disclosed which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. The compounds disclosed include 3-benzyloxybenzamides, 3-oxybenzamides in which a chain of 5 or more methylene groups terminate in a halogen atom or in a purin-9-yl moiety, certain benzoxazole-4-carboxamide compounds and certain quinazolinone compounds. In formula X and Y together may form a bride --X--Y-- that represents the grouping (a), (b) or (c )wherein R.sup.5 is H, alkyl, aryl or aralkyl.

  揭示了一系列3-氧苯甲酰胺化合物和相关的喹唑啉酮化合物，它们可以作为DNA修复酶聚(ADP-核糖)聚合酶或PARP酶（EC 2.4.2.30）的有效抑制剂，并且因此可以提供用于与损伤DNA的细胞毒性药物或放疗结合使用以增强后者效果的有用治疗化合物。所披露的化合物包括3-苄氧基苯甲酰胺、3-氧基苯甲酰胺，其中5个或更多亚甲基基团的链以卤原子或吡嗪-9-基团结尾，某些苯并噁唑-4-甲酰胺化合物和某些喹唑啉酮化合物。在公式X和Y中，X和Y一起可以形成代表基团(a)、(b)或(c)的桥--X--Y--，其中R.sup.5为H、烷基、芳基或芳基烷基。
• A Novel Class of Orally Active Non-Peptide Bradykinin B₂ Receptor Antagonists. 3. Discovering Bioisosteres of the Imidazo[1,2-<i>a</i>]pyridine Moiety
  作者：Yoshito Abe、Hiroshi Kayakiri、Shigeki Satoh、Takayuki Inoue、Yuki Sawada、Noriaki Inamura、Masayuki Asano、Ichiro Aramori、Chie Hatori、Hiroe Sawai、Teruo Oku、Hirokazu Tanaka

  DOI：10.1021/jm980300f

  日期：1998.10.1

  Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2, 6-dichlorobenzyl]oxy]-3-halo-2-methylimidazo[1,2-a]pyridine skeleton, leading to identification of the first clinical candidate 4a (FR167344). With this potent new lead compound in hand, we then investigated

  最近，我们报道了克服我们的第一个口服活性非肽缓激肽（BK）B2受体拮抗剂的物种差异，该拮抗剂结合了8-[[[3-（N-酰基甘氨酰-N-甲基氨基）-2，6-二氯苄基]氧基] -3-卤代-2-甲基咪唑并[1,2-a]吡啶骨架，导致鉴定出第一个临床候选药物4a（FR167344）。有了这种有效的新的先导化合物，我们随后研究了通过取代咪唑并[1,2-a]吡啶部分进一步完善基本骨架的方法，并发现了几个生物等排杂环。这些新型杂芳族衍生物的广泛优化揭示了咪唑并[1,2-a]吡啶环和2,6-二氯苄基部分周围的详细结构-活性关系（SAR），导致发现我们的第二个临床候选药物87b（FR173657），该药物抑制[3H] BK与在中国仓鼠卵巢（CHO）细胞和表达B2受体的豚鼠回肠膜制剂中表达的重组人B2受体的特异性结合，IC50为1.4和分别为0.46 nM。该化合物还显示出对豚鼠BK诱导的支气管收缩的优异体内功能拮抗活性，口服给药的ED50值为0